The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Oligonucleotide Therapies: The Past and the Present
Open accessAbstract
In this review we address the development of oligonucleotide (ON) medicines from a historical perspective by listing the landmark discoveries in this field. The various biological processes that have been targeted and the corresponding ON interventions found in the literature are discussed together with brief updates on some of the more recent developments. Most ON therapies act through antisense mechanisms and are directed against various RNA species, as exemplified by gapmers, steric block ONs, antagomirs, small interfering RNAs (siRNAs), micro-RNA mimics, and splice switching ONs. However, ONs binding to Toll-like receptors and those forming aptamers have completely different modes of action. Similar to other novel medicines, the path to success has been lined with numerous failures, where different therapeutic ONs did not stand the test of time. Since the first ON drug was approved for clinical use in 1998, the therapeutic landscape has changed considerably, but many challenges remain until the expectations for this new form of medicine are met. However, there is room for cautious optimism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cannata, F., Brunet, E., Perrouault, L., Roig, V., Ait‐Si‐Ali, S., Asseline, U., Concordet, J., & Giovannangeli, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710433105 · Cited by 19
RetractedA Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid
WATSON, J. D., & CRICK, F. H. C. (1953) · Nature · doi:10.1038/171737a0 · Cited by 13,584
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“that bacterial CpG triggers the activation of Blymphocytes,(12) and this was followed by the cloning of the corresponding receptor, named TLR9, in the year 2000.(13) While the TLR intracellular signaling pathways have been delineated,(14) it is interesting to note that short DNA ONs impair TLR3 signaling in both prima…”
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332
STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES
Avery, O. T., MacLeod, C. M., & McCarty, M. (1944) · Journal of Experimental Medicine · doi:10.1084/jem.79.2.137 · Cited by 2,683
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
HELIX FORMATION BY GUANYLIC ACID
Gellert, M., Lipsett, M. N., & Davies, D. R. (1962) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.48.12.2013 · Cited by 1,643
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Sequence-Specific Cleavage of Double Helical DNA by Triple Helix Formation
Moser, H. E., & Dervan, P. B. (1987) · Science · doi:10.1126/science.3118463 · Cited by 1,284
Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Sinha, N. D., Biernat, J., McManus, J., & Köster, H. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.11.4539 · Cited by 849
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D., Yu, R., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 845
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes.
Field, A. K., Tytell, A. A., Lampson, G. P., & Hilleman, M. R. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.58.3.1004 · Cited by 708
Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid
Watson, J. D., & Crick, F. H. C. (2004) · Resonance · doi:10.1007/bf02834980 · Cited by 656
Gene regulation by antisense transcription
Pelechano, V., & Steinmetz, L. M. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3594 · Cited by 634
Obika, S., Nanbu, D., Hari, Y., Morio, K.-I., In, Y., Ishida, T., & Imanishi, T. (1997) · Tetrahedron Letters · doi:10.1016/s0040-4039(97)10322-7 · Cited by 610
Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F., & Krainer, A. R. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.014 · Cited by 574
Exosomes for targeted siRNA delivery across biological barriers
EL Andaloussi, S., Lakhal, S., Mäger, I., & Wood, M. J. A. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.008 · Cited by 539
Molecular basis of muscular dystrophies
Cohn, R. D., & Campbell, K. P. (2000) · Muscle & Nerve · doi:10.1002/1097-4598(200010)23:10<1456::aid-mus2>3.0.co;2-t · Cited by 538
Hoogsteen, K. (1963) · Acta Crystallographica · doi:10.1107/s0365110x63002437 · Cited by 492
(1984) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/72.4.955 · Cited by 466
Singh, N. K., Singh, N. N., Androphy, E. J., & Singh, R. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1333-1346.2006 · Cited by 454
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Chemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Takeda, K., & Akira, S. (2015) · Current Protocols in Immunology · doi:10.1002/0471142735.im1412s109 · Cited by 421
Allele-specific silencing of dominant disease genes
Miller, V. M., Xia, H., Marrs, G. L., Gouvion, C. M., Lee, G., Davidson, B. L., & Paulson, H. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1231012100 · Cited by 400
Site specific enzymatic cleavage of RNA
Donis-Keller, H. (1979) · Nucleic Acids Research · doi:10.1093/nar/7.1.179 · Cited by 399
Takeda, K., & Akira, S. (2007) · Current Protocols in Immunology · doi:10.1002/0471142735.im1412s77 · Cited by 378
Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides
Bielinska, A., Shivdasani, R. A., Zhang, L., & Nabel, G. J. (1990) · Science · doi:10.1126/science.2237444 · Cited by 372
Usman, N., Ogilvie, K. K., Jiang, M. Y., & Cedergren, R. J. (1987) · Journal of the American Chemical Society · doi:10.1021/ja00259a037 · Cited by 366
Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S. E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T., et al. (2015) · Nature Medicine · doi:10.1038/nm.3765 · Cited by 327
Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA
Egholm, M., Christensen, L., Deuholm, K. L., Buchardt, O., Coull, J., & Nielsen, P. E. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.2.217 · Cited by 309
Correction of disease-associated exon skipping by synthetic exon-specific activators
Cartegni, L., & Krainer, A. R. (2003) · Nature Structural Biology · doi:10.1038/nsb887 · Cited by 301
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 294
microRNAs in the Regulation of Adipogenesis and Obesity
A. McGregor, R., & S. Choi, M. (2011) · Current Molecular Medicine · doi:10.2174/156652411795677990 · Cited by 287
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
Skordis, L. A., Dunckley, M. G., Yue, B., Eperon, I. C., & Muntoni, F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0633863100 · Cited by 274
Halperin, S. A., Van Nest, G., Smith, B., Abtahi, S., Whiley, H., & Eiden, J. J. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00045-8 · Cited by 259
Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer® therapeutics
Vater, A., & Klussmann, S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.004 · Cited by 250
Hu, J., Matsui, M., Gagnon, K. T., Schwartz, J. C., Gabillet, S., Arar, K., Wu, J., Bezprozvanny, I., & Corey, D. R. (2009) · Nature Biotechnology · doi:10.1038/nbt.1539 · Cited by 243
Kanazawa, T., Akiyama, F., Kakizaki, S., Takashima, Y., & Seta, Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.036 · Cited by 241
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy
Zhou, J., & Rossi, J. J. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.21 · Cited by 234
Campbell, J. M., Bacon, T. A., & Wickstrom, E. (1990) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(90)90084-p · Cited by 230
CIII. Total synthesis of the structural gene for an alanine transfer ribonucleic acid from yeast
Khorana, H. G., Agarwal, K. L., Büchi, H., Caruthers, M. H., Gupta, N. K., Klbppe, K., Kumar, A., Ohtsuka, E., RajBhandary, U. L., van de Sande, J. H., et al. (1972) · Journal of Molecular Biology · doi:10.1016/0022-2836(72)90146-5 · Cited by 200
Improved silencing properties using small internally segmented interfering RNAs
Bramsen, J. B., Laursen, M. B., Damgaard, C. K., Lena, S. W., Ravindra Babu, B., Wengel, J., & Kjems, J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm548 · Cited by 192
Lönnberg, H. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800406a · Cited by 187
Rajeev, K. G., Nair, J. K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J. L. S., Yucius, K., Nguyen, T., Shulga‐Morskaya, S., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500023 · Cited by 185
Antitumorigenic potential of STAT3 alternative splicing modulation
Zammarchi, F., de Stanchina, E., Bournazou, E., Supakorndej, T., Martires, K., Riedel, E., Corben, A. D., Bromberg, J. F., & Cartegni, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108482108 · Cited by 176
Shan, Y., Zheng, J., Lambrecht, R. W., & Bonkovsky, H. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.002 · Cited by 165
Østergaard, M. E., Southwell, A. L., Kordasiewicz, H., Watt, A. T., Skotte, N. H., Doty, C. N., Vaid, K., Villanueva, E. B., Swayze, E. E., Frank Bennett, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt725 · Cited by 163
Bayever, E., Iversen, P. L., Bishop, M. R., Sharp, J. G., Tewary, H. K., Arneson, M. A., Pirruccello, S. J., Ruddon, R. W., Kessinger, A., Zon, G., et al. (1993) · Antisense Research and Development · doi:10.1089/ard.1993.3.383 · Cited by 149
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts
Ni, X., Zhang, Y., Ribas, J., Chowdhury, W. H., Castanares, M. A., Zhang, Z., Laiho, M., DeWeese, T. L., & Lupold, S. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45109 · Cited by 143
Induction of splice correction by cell‐penetrating peptide nucleic acids
Andaloussi, S. E., Johansson, H. J., Lundberg, P., & Langel, Ü. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.950 · Cited by 141
Gagnon, K. T., Pendergraff, H. M., Deleavey, G. F., Swayze, E. E., Potier, P., Randolph, J., Roesch, E. B., CHATTOPADHYAYA, J. B., Damha, M. J., Bennett, C. F., et al. (2010) · Biochemistry · doi:10.1021/bi101208k · Cited by 140
Đapić, V., Bates, P. J., Trent, J. O., Rodger, A., Thomas, S. D., & Miller, D. M. (2002) · Biochemistry · doi:10.1021/bi0119520 · Cited by 140
Cellular uptake and intracellular trafficking of oligonucleotides
Juliano, R. L., & Carver, K. A. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.005 · Cited by 140
Juliano, R. L., Ming, X., Carver, K. A., & Laing, B. M. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0463 · Cited by 135
Piva, R., Spandidos, D. A., & Gambari, R. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2059 · Cited by 132
Effects of Sequence of Thioated Oligonucleotides on Cultured Human Mammary Epithelial Cells
Yaswen, P., Stampfer, M. R., GHOSH, K., & Cohen, J. S. (1993) · Antisense Research and Development · doi:10.1089/ard.1993.3.67 · Cited by 128
Aptamer-Mediated Delivery of Splice-Switching Oligonucleotides to the Nuclei of Cancer Cells
Kotula, J. W., Pratico, E. D., Ming, X., Nakagawa, O., Juliano, R. L., & Sullenger, B. A. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0347 · Cited by 124
Zhou, J., Neff, C. P., Swiderski, P. M., Li, H., Smith, D. D., Aboellail, T., Remling‐Mulder, L., Akkina, R., & Rossi, J. J. (2012) · Molecular Therapy · doi:10.1038/mt.2012.226 · Cited by 122
Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302)
Watanabe, T. A., Geary, R. S., & Levin, A. A. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.169 · Cited by 120
Eckstein, F. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00970a054 · Cited by 116
Stirchak, E. P., Summerton, J. E., & Weller, D. D. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.15.6129 · Cited by 115
Biological Activity and Biotechnological Aspects of Peptide Nucleic Acid
Lundin, K. E., Good, L., Strömberg, R., Gräslund, A., & Smith, C. I. E. (2006) · Advances in genetics · doi:10.1016/s0065-2660(06)56001-8 · Cited by 114
Self-citationEckstein, F. (1970) · Journal of the American Chemical Society · doi:10.1021/ja00718a039 · Cited by 111
Turunen, M. P., Lehtola, T., Heinonen, S. E., Assefa, G. S., Korpisalo, P., Girnary, R., Glass, C. K., Vaïsänen, S., & Ylä‐Herttuala, S. (2009) · Circulation Research · doi:10.1161/circresaha.109.200774 · Cited by 107
Biological activity and biotechnological aspects of locked nucleic acids.
Lundin, K. E., Højland, T., Hansen, B. R., Persson, R., Bramsen, J., Kjems, J., Koch, T., Wengel, J., & Smith, C. E. (2013) · Advances in Genetics · doi:10.1016/b978-0-12-407676-1.00002-0 · Cited by 99
Self-citationModeling, synthesis, and hybridization properties of (L)-ribonucleic acid
Ashley, G. W. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00051a001 · Cited by 93
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
Antisense Oligonucleotides for the Treatment of Spinal Muscular Atrophy
Porensky, P. N., & Burghes, A. H. M. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.225 · Cited by 92
NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease
Lukiw, W. J. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt150 · Cited by 87
Bobst, A. M., ROTTMAN, F. M., & Cerutti, P. (1969) · Journal of Molecular Biology · doi:10.1016/0022-2836(69)90418-5 · Cited by 80
Development of Therapeutic Splice-Switching Oligonucleotides
Disterer, P., Kryczka, A., Liu, Y., Badi, Y. E., Wong, J. J., Owen, J. S., & Khoo, B. C. E. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.234 · Cited by 71
Superior Duplex DNA Strand Invasion by Acridine Conjugated Peptide Nucleic Acids
Bentin, T., & Nielsen, P. E. (2003) · Journal of the American Chemical Society · doi:10.1021/ja029936t · Cited by 70
Skipping Multiple Exons of Dystrophin Transcripts Using Cocktail Antisense Oligonucleotides
Echigoya, Y., & Yokota, T. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0451 · Cited by 57
Antisense therapeutics in oncology: current status
Farooqı, A. A., Marwat, Z., & Muntané, J. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s49652 · Cited by 55
Silencing human genetic diseases with oligonucleotide-based therapies
Martínez, T., Wright, N., López‐Fraga, M., Jiménez, A. I., & Pañeda, C. (2013) · Human Genetics · doi:10.1007/s00439-013-1288-1 · Cited by 50
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model
Bestas, B., Moreno, P. M. D., Blomberg, K. E. M., Mohammad, D. K., Saleh, A. F. A., Sütlü, T., Nordin, J. Z., Guterstam, P., Gustafsson, M. O., Kharazi, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76175 · Cited by 49
Self-citationParamasivam, M., Cogoi, S., Filichev, V. V., Bomholt, N., Pedersen, E. B., & Xodo, L. E. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn242 · Cited by 45
Fluiter, K., Mook, O. R. F., Vreijling, J. P., Langkjær, N., Højland, T., Wengel, J., & Baas, F. (2009) · Molecular BioSystems · doi:10.1039/b903922h · Cited by 45
Liu, J., Pendergraff, H. M., Jayaprakash, K. N., Lackey, J. G., Kuchimanchi, S., Rajeev, K. G., Manoharan, M., Hu, J., & Corey, D. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt594 · Cited by 45
Redirecting splicing with bifunctional oligonucleotides
Brosseau, J., Lucier, J., Lamarche, A.-A., Shkreta, L., Gendron, D., Lapointe, E., Thibault, P., Paquet, É. R., Perreault, J., Elela, S. A., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1287 · Cited by 44
Westerlind, U., Westman, J., Törnquist, E., Smith, C. I. E., Oscarson, S., Lahmann, M., & Norberg, T. (2004) · Glycoconjugate Journal · doi:10.1023/b:glyc.0000045095.86867.c0 · Cited by 42
Self-citationChauhan, N. B., & Siegel, G. J. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.01.008 · Cited by 40
Sun, X., Marque, L. O., Cordner, Z. A., Pruitt, J. L., Bhat, M., Li, P. P., Kannan, G., Ladenheim, E. E., Moran, T. H., Margolis, R. L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu349 · Cited by 40
Nielsen, T. Ø., Sorensen, S., Dagnæs‐Hansen, F., Kjems, J., & Sørensen, B. S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.247 · Cited by 38
Allele-Selective Inhibition of Mutant Atrophin-1 Expression by Duplex and Single-Stranded RNAs
Hu, J., Liu, J., Jayaprakash, K. N., Lackey, J. G., Kuchimanchi, S., Rajeev, K. G., Manoharan, M., Swayze, E. E., Lima, W. F., Prakash, T. P., et al. (2014) · Biochemistry · doi:10.1021/bi500610r · Cited by 36
Potential of Anti‐Cancer Therapy Based on Anti‐miR‐155 Oligonucleotides in Glioma and Brain Tumours
Poltronieri, P., D'Urso, P., Mezzolla, V., & D'Urso, O. F. (2013) · Chemical Biology and Drug Design · doi:10.1111/cbdd.12002 · Cited by 35
Fomiversen Sodium Approved to Treat CMV Retinitis
Piascik, P. (1999) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)30428-4 · Cited by 32
Palhais, B., Præstegaard, V. S., Sabaratnam, R., Doktor, T. K., Lutz, S., Burda, P., Suormala, T., Baumgartner, M. R., Fowler, B., Bruun, G. H., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv275 · Cited by 31
Zorro locked nucleic acid induces sequence‐specific gene silencing
Ge, R., Heinonen, J. E., Svahn, M. G., Mohamed, A. J., Lundin, K. E., & Smith, C. I. E. (2007) · The FASEB Journal · doi:10.1096/fj.06-7225com · Cited by 29
Self-citationRecognition of Chromosomal DNA inside Cells by Locked Nucleic Acids
Beane, R. L., Gabillet, S., Montaillier, C., Arar, K., & Corey, D. R. (2008) · Biochemistry · doi:10.1021/bi801930p · Cited by 28
Splicing therapeutics in SMN2 and APOB.
Khoo, B. C. E., & Krainer, A. R. (2009) · PubMed · Cited by 27
Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge
Colombo, S., Zeng, X., Ragelle, H., & Foged, C. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.927439 · Cited by 27
Sköld, A. E., Hasan, M., Vargas, L., Saïdi, H., Dereuddre‐Bosquet, N., Grand, R. L., Smith, C. I. E., & Spetz, A. (2012) · Blood · doi:10.1182/blood-2011-12-397778 · Cited by 27
Self-citationBoulware, S. B., Christensen, L. A., Thames, H. D., Coghlan, L., Vásquez, K. M., & Finch, R. A. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22026 · Cited by 25
Lundin, K. E., Hasan, M., Moreno, P. M. D., et al. (2005) · Biomolecular Engineering · doi:10.1016/j.bioeng.2005.07.003 · Cited by 22
Self-citationMultifunctional Nucleic Acids for Tumor Cell Treatment
Pofahl, M., Wengel, J., & Mayer, G. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0472 · Cited by 22
RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form
Rocha, C. S. J., Wiklander, O. P. B., Larsson, L., Moreno, P. M. D., Parini, P., Lundin, K. E., & Smith, C. I. E. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.03.009 · Cited by 20
Self-citationSplice-Correction Strategies for Treatment of X-Linked Agammaglobulinemia
Bestas, B., Turunen, J. J., Blomberg, K. E. M., Wang, Q., Månsson, R., Andaloussi, S. E., Berglöf, A., & Smith, C. I. E. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0510-0 · Cited by 19
Self-citationFomivirsen approved for CMV retinitis: first antisense drug.
(1998) · PubMed · Cited by 13
Ge, R., Svahn, M. G., Simonson, O. E., Mohamed, A. J., Lundin, K. E., & Smith, C. I. E. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1124 · Cited by 11
Self-citationLing, J. Q., Hou, A., & Hoffman, A. R. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.11.004 · Cited by 7
Design and Application of Bispecific Splice-Switching Oligonucleotides
Bestas, B., McClorey, G., Tedebark, U., Moreno, P. M. D., Roberts, T. C., Hammond, S. M., Smith, C. I. E., Wood, M. J. A., & Andaloussi, S. E. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0462 · Cited by 6
Self-citation
Cited by
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Boeynaems, S., Holehouse, A. S., Weinhardt, V., Kovacs, D., Van Lindt, J., Larabell, C., Van Den Bosch, L., Das, R., Tompa, P. S., Pappu, R. V., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821038116 · Cited by 482
Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development
Schulz, S., Becker, M., Groseclose, M. R., Schadt, S., & Hopf, C. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.08.003 · Cited by 325
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
Self-citationO’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Metadata
- Authors
- Lundin, K. E., Gissberg, O., & Smith, C. I. E.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2015-08
- Volume
- 26
- Issue
- 8
- Pages
- 475-485
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1952915322
- Cited by
- 267
- References
- 127
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.